/
BOLD
$2.45-$0.11 (-4.30%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$57.5M
22M shares
52-week range
$0.96 – $2.79
81% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-11.80
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M | $1.3M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$1.1M | −$1.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $48.8M | $75.9M | $104.4M | $19.3M | $37.2M | $42.6M | $55.3M | $44.8M |
| Operating income | −$60.0M | −$93.2M | −$134.4M | −$25.3M | −$46.5M | −$54.8M | −$73.3M | −$63.6M |
| EBITDA | −$58.1M | −$88.7M | −$121.4M | −$24.5M | −$45.0M | −$48.5M | −$64.3M | −$56.9M |
| Net income | −$59.7M | −$90.2M | −$128.8M | −$25.2M | −$45.9M | −$49.4M | −$65.4M | −$58.2M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5.59 | -3.40 | -2.93 | -1.13 | -2.06 | -2.22 | -3.85 | -2.60 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.44 | $-2.44–$-2.44 | 1 |
| 2027 | $0 | $-1.43 | $-1.43–$-1.43 | 1 |
| 2028 | $8M | $-1.56 | $-1.56–$-1.56 | 1 |
| 2029 | $0 | $-1.34 | $-1.34–$-1.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Boundless Bio, Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
www.boundlessbio.com- Employees
- 28
- IPO / List date
- Mar 28, 2024
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds BOLD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 399,000 | $438.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BOLD yet.
